五项研究的持续葡萄糖监测指标识别有1型糖尿病发病风险的参与者
研究纳入五项研究中≥1种胰岛自身抗体阳性的参与者,评估持续葡萄糖监测(CGM)指标能否预测3期1型糖尿病诊断;全模型(特征+CGM指标)C统计量为0.74(95%CI 0.66, 0.81),高于仅特征模型(0.69;95%CI 0.60, 0.77)和仅CGM模型(0.68;95%CI 0.61, 0.75);全模型低、中、高风险组2年内出现症状性疾病的概率分别为5%、13%和48%。
要点
- 全模型预测3期1型糖尿病诊断的C统计量为0.74(95%CI 0.66, 0.81),高于仅特征模型(0.69)和仅CGM模型(0.68)。
- 血糖>7.8 mmol/l时间百分比更高(p<0.001)、HbA1c更高(p=0.02)、有一级亲属患1型糖尿病(p=0.02)和IA-2自身抗体阳性(p<0.001)与1型糖尿病诊断风险更高相关。
- 全模型低(n=79)、中(n=98)、高风险(n=41)组2年内出现症状性疾病的概率分别为5%、13%和48%。
核心结论
- CGM指标可帮助预测疾病进展,并结合其他因素对个体1型糖尿病诊断风险进行分类。
- CGM还可用于更好地评估1型糖尿病进展风险并确定潜在预防试验的入选资格。
研究设计与样本
- 基线CGM数据来自五项研究中≥1种胰岛自身抗体阳性的参与者:ASK(n=79)、BDR(n=22)、DAISY(n=18)、DIPP(n=8)和TrialNet Pathway to Prevention(n=91)。
- 中位随访时间为2.6年(四分位数:1.5至3.6年)。
- 比较了仅参与者特征模型、仅CGM指标模型以及结合特征和CGM指标的全模型。
主要发现
- 全模型预测3期1型糖尿病诊断的C统计量为0.74(95%CI 0.66, 0.81),仅特征模型为0.69(95%CI 0.60, 0.77),仅CGM模型为0.68(95%CI 0.61, 0.75)。
- 血糖>7.8 mmol/l时间百分比更高(p<0.001)、HbA1c(p=0.02)、有一级亲属患1型糖尿病(p=0.02)和IA-2自身抗体阳性(p<0.001)与1型糖尿病诊断风险更高相关。
- 男性(p=0.06)和GAD自身抗体阴性(p=0.09)被选入但未发现显著。
- 全模型分类为低风险(n=79)、中风险(n=98)和高风险(n=41)的参与者2年内出现症状性疾病的概率分别为5%、13%和48%。
临床怎么用
- 作者认为,CGM指标可帮助预测疾病进展,并结合其他因素对个体1型糖尿病诊断风险进行分类。
- 作者认为,CGM还可用于更好地评估1型糖尿病进展风险并确定潜在预防试验的入选资格。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: We aimed to assess whether continuous glucose monitor (CGM) metrics can accurately predict stage 3 type 1 diabetes diagnosis in those with islet autoantibodies (AAb). METHODS: Baseline CGM data were collected from participants with ≥1 positive AAb type from five studies: ASK (n=79), BDR (n=22), DAISY (n=18), DIPP (n=8) and TrialNet Pathway to Prevention (n=91). Median follow-up time was 2.6 years (quartiles: 1.5 to 3.6 years). A participant characteristics-only model, a CGM metrics-only model and a full model combining characteristics and CGM metrics were compared. RESULTS: The full model achieved a numerically higher performance predictor estimate (C statistic=0.74; 95% CI 0.66, 0.81) for predicting stage 3 type 1 diabetes diagnosis compared with the characteristics-only model (C statistic=0.69; 95% CI 0.60, 0.77) and the CGM-only model (C statistic=0.68; 95% CI 0.61, 0.75). Greater percentage of time >7.8 mmol/l (p<0.001), HbA1c (p=0.02), having a first-degree relative with type 1 diabetes (p=0.02) and testing positive for IA-2 AAb (p<0.001) were associated with greater risk of type 1 diabetes diagnosis. Additionally, being male (p=0.06) and having a negative GAD AAb (p=0.09) were selected but not found to be significant. Participants classified as having low (n=79), medium (n=98) or high (n=41) risk of stage 3 type 1 diabetes diagnosis using the full model had a probability of developing symptomatic disease by 2 years of 5%, 13% and 48%, respectively. CONCLUSIONS/INTERPRETATION: CGM metrics can help predict disease progression and classify an individual's risk of type 1 diabetes diagnosis in conjunction with other factors. CGM can also be used to better assess the risk of type 1 diabetes progression and define eligibility for potential prevention trials.
引用
- Calhoun P, Spanbauer C, Steck AK, et al. Continuous glucose monitor metrics from five studies identify participants at risk for type 1 diabetes development. Diabetologia. 2025. PMID: 39934369. doi:10.1007/s00125-025-06362-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。